Clinical Trials Logo

Clinical Trial Summary

Integrative analysis of GBM


Clinical Trial Description

The investigators will analyzed proteomes of paired normal brain tissues and GBM, sequenced transcriptomes, perform whole exome sequencing, and single nucleotide polymorphism (SNP) array profiling for triplets, each comprising normal brain tissue, primary GBM carcinoma, and its synchronous matched metastasis, as well as analyzed genomics of GBM characterized previously by The Cancer Genome Atlas (TCGA) to conduct integrated proteogenomic analyses. ;


Study Design

Observational Model: Case Control, Time Perspective: Retrospective


Related Conditions & MeSH terms


NCT number NCT03005132
Study type Observational
Source Shanghai 10th People's Hospital
Contact Da Fu, PhD
Phone 00-86-21-66301604
Email [email protected]
Status Recruiting
Phase N/A
Start date January 2016
Completion date December 2026

See also
  Status Clinical Trial Phase
Terminated NCT03149575 - VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM Phase 3
Recruiting NCT04528680 - Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel for Recurrent Glioblastoma Phase 1/Phase 2
Completed NCT01478178 - Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma Phase 1/Phase 2
Completed NCT03119064 - BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma Phase 1/Phase 2
Recruiting NCT03758014 - Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Grade IV GBM Patients Phase 2/Phase 3
Terminated NCT01205334 - Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme Phase 1/Phase 2
Active, not recruiting NCT00114309 - 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma Phase 2
Not yet recruiting NCT03746288 - To Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Recurrent Glioblastoma (GBM) Phase 2
Completed NCT01856933 - BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM) Phase 2
Recruiting NCT04763031 - Recurrent GBM With Maximal Neurosurgical Removal and Treatment With IORT N/A
Completed NCT00107003 - GW572016 to Treat Recurrent Malignant Brain Tumors Phase 2
Recruiting NCT03426891 - Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma Phase 1
Recruiting NCT04115761 - Evaluate the Efficacy and Safety of ADCV01 as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients Phase 2
Recruiting NCT03341806 - Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma Phase 1
Recruiting NCT02861898 - Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma Phase 1/Phase 2
Recruiting NCT04391595 - LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients Early Phase 1
Recruiting NCT03630289 - Surgical Tissue Flap to Bypass the Blood Brain Barrier in GBM N/A
Recruiting NCT04424966 - Infigratinib in Recurrent High-Grade Glioma Patients Early Phase 1
Completed NCT02207010 - A Phase 0 Study of AZD1775 in Recurrent GBM Patients Early Phase 1
Recruiting NCT04222309 - Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM) Phase 1